NIH R01 · 2024
Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment
PROJECT SUMMARY Glioblastoma (GBM), the most common malignant brain tumor and one of the most fatal of cancers, remains impervious to treatment with the current standard of care (SOC) therapies. Even immunotherapies like immune checkpoint inhibitors (ICI) have failed for GBM despite their success with other cancers. One critical reason for this failure is that the brain’s GBM tumor microenvironment (TME) is highly immunosuppressive. To change the GBM microenvironment, over the last period of funding we have been exploring the use of oncolytic viruses (OV), based on herpes simplex virus type 1 (oHSV). Of relevance, we have completed a “first-in-human” clinical trial in subjects with GBM.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.